Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

4 de setembro de 2019 atualizado por: Radiation Therapy Oncology Group

A Phase II Trial Of Neoadjuvant Therapy With Concurrent Chemotherapy And High Dose Radiotherapy Followed By Surgical Resection And Consolidative Therapy For Locally Advanced Non-Small Cell Lung Carcinoma

RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving paclitaxel and carboplatin together with radiation therapy before surgery may shrink the tumor so that it can be removed. Giving chemotherapy after surgery may kill any tumor cells remaining after surgery.

PURPOSE: This phase II trial is studying how well giving paclitaxel and carboplatin together with radiation therapy works in treating patients who are undergoing surgery for stage III non-small cell lung cancer.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

OBJECTIVES:

  • Determine the mediastinal node clearance rate in patients with stage IIIA or IIIB non-small cell lung cancer treated with neoadjuvant induction chemoradiotherapy comprising paclitaxel, carboplatin, and high-dose radiotherapy followed by surgical resection for patients found to be resectable and consolidative chemotherapy comprising paclitaxel and carboplatin.
  • Determine the rate of complete pathological response in patients treated with this regimen.
  • Determine the feasibility of surgical resection after neoadjuvant induction chemoradiotherapy in these patients.
  • Determine disease-free and overall survival of patients treated with this regimen.
  • Determine the toxicity of this regimen in these patients.

Tipo de estudo

Intervencional

Inscrição (Real)

60

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Estados Unidos
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85013
        • Arizona Oncology Services Foundation
      • Scottsdale, Arizona, Estados Unidos, 85260
        • Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea
    • California
      • Los Angeles, California, Estados Unidos, 90089-9181
        • USC/Norris Comprehensive Cancer Center and Hospital
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32224
        • Mayo Clinic - Jacksonville
      • Tallahassee, Florida, Estados Unidos, 32308
        • Tallahassee Memorial Hospital
    • Illinois
      • Springfield, Illinois, Estados Unidos, 62702
        • Cancer Institute at St. John's Hospital
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • Greenebaum Cancer Center at University of Maryland Medical Center
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48106-0995
        • Saint Joseph Mercy Cancer Center
      • Ann Arbor, Michigan, Estados Unidos, 48106
        • CCOP - Michigan Cancer Research Consortium
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic Cancer Center
    • Missouri
      • Saint Louis, Missouri, Estados Unidos, 63110
        • Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68114
        • Methodist Estabrook Cancer Center
    • New Jersey
      • Camden, New Jersey, Estados Unidos, 08103
        • Cancer Institute of New Jersey at Cooper University Hospital - Camden
      • Voorhees, New Jersey, Estados Unidos, 08043
        • Cancer Institute of New Jersey at Cooper - Voorhees
    • North Carolina
      • Greenville, North Carolina, Estados Unidos, 27835-6028
        • Leo W. Jenkins Cancer Center at ECU Medical School
    • Pennsylvania
      • Bethlehem, Pennsylvania, Estados Unidos, 18015
        • St. Luke's Cancer Network at St. Luke's Hospital
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Hollings Cancer Center at Medical University of South Carolina
    • Tennessee
      • Kingsport, Tennessee, Estados Unidos, 37662
        • Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center
    • West Virginia
      • Wheeling, West Virginia, Estados Unidos, 26003
        • Schiffler Cancer Center at Wheeling Hospital
    • Wisconsin
      • Green Bay, Wisconsin, Estados Unidos, 54307-3508
        • St. Vincent Hospital Regional Cancer Center
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Medical College of Wisconsin Cancer Center
      • Milwaukee, Wisconsin, Estados Unidos, 53295
        • Veterans Affairs Medical Center - Milwaukee

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Patients with Stage IIIA (T1-3 N2) or Stage IIIB (N3, excluding supraclavicular involvement) non-small cell lung cancer documented by biopsy or cytology (Pancoast tumors are eligible if pathologic evidence of mediastinal nodal disease is present);
  2. Disease must be measurable;
  3. Mediastinal lymph nodes must be proven positive by pathologic review. All patients must undergo mediastinoscopy, thoracoscopy, Chamberlain procedure, or transbronchial needle aspirate to evaluate extent of nodal involvement. Any lymph node assessed by mediastinoscopy and found to be positive will be defined as N2 disease;
  4. Patients ≥ 18 years of age;
  5. Life expectancy ≥ 6 months;
  6. Zubrod performance status 0- 1 (See Appendix II);
  7. Pretreatment laboratory values must be as follows: White blood cell count (WBC) count: ≥ 3,000/mm^3; Absolute granulocyte count: ≥ 1,500/mm^3; Platelets: ≥ 100,000/mm3; Total bilirubin: ≤ 1.5 x institutional upper limit of normal (ULN); Serum creatinine: ≤ 1.5 x institutional ULN; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x institutional ULN; serum albumin: ≥ 3.0 g/dL
  8. Baseline forced expiratory volume (FEV1) must be at least 2.0 liters; if less than 2.0 then V/Q scan is required and projected post-operative FEV1 must be > 800 cc based on the following formula using the quantitative Ventilation/perfusion (V/Q) scan: FEV1 = FEV1 x % perfusion to uninvolved lung from quantitative lung V/Q scan report.
  9. Patient evaluation and acceptance by thoracic surgery, medical oncology, and radiation oncology; patient must be a potential surgical candidate prior to the initiation of therapy;
  10. Women of childbearing potential and male participants must practice an effective method of contraception during the study;

  11. Pretreatment evaluations required for eligibility include:

    • A complete medical history & physical examination to include Zubrod performance status, neurologic assessment, recent weight loss, usual weight, concurrent non-malignant disease and therapy;
    • Location, type, and size of measurable lesion must be recorded prior to treatment;
    • Complete blood count (CBC) with differential, platelet count, electrolytes, and Mg++ within 14 days prior to study entry;
    • Twelve-channel serum multiple analysis (SMA-12): Total protein, Albumin, Calcium, Glucose, Blood urea nitrogen (BUN), Creatinine, Alkaline Phosphatase, Lactate dehydrogenase (LDH), Total Bilirubin, serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) within 14 days prior to study entry;
    • Women of childbearing potential must have a negative pre-study serum or urine pregnancy test within 14 days prior to study entry.
    • Mediastinoscopy, thoracoscopy, Chamberlain procedure, or bronchoscopy with transbronchial needle aspirate to evaluate the extent of lymph node involvement;
    • Computed tomography (CT) scan of the chest to include liver, and adrenal glands within 6 weeks prior to study entry;
    • Positron emission tomography (PET) scan within 8 weeks prior to study entry. Any suspicious areas outside of the local regional disease requires documented evaluation of these findings to exclude metastatic disease;
    • CT scan or magnetic resonance imaging (MRI) of the brain within 6 weeks prior to study entry;
    • Electrocardiogram (EKG) and pulmonary function tests including forced vital capacity (FVC), FEV-1, and diffusing capacity of carbon monoxide (DLCO), within 8 weeks prior to study entry; V/Q scan, if applicable, within 8 weeks prior to study entry.
  12. Patients must sign a study-specific informed consent prior to study entry.

Exclusion Criteria:

  1. Small cell lung cancer; distant metastatic disease;
  2. Evidence of clinical or radiographic supraclavicular lymph node involvement;
  3. Bronchioalveolar carcinoma with lobar or multilobar involvement;
  4. Unintentional weight loss > 5% within 6 months prior to study entry, or Zubrod performance status 2 or greater;
  5. Primary tumor location prevents delivery of 60 Gy and simultaneously limiting spinal cord dose to 48 Gy;
  6. Patients with malignant pleural effusion;
  7. Clinically evident superior vena cava syndrome;
  8. Prior systemic chemotherapy or radiation therapy to the thorax;
  9. Patients with known hypersensitivity to Cremophor EL;
  10. Patients receiving other investigational therapy;
  11. Pregnant or lactating women are ineligible, as treatment involves unforeseeable risks to the participant and to the embryo or fetus;
  12. Patients with an active serious infection or other serious underlying medical condition that would impair their ability to complete protocol treatment;
  13. Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Chemoradiation, Surgery, Chemotherapy
Induction paclitaxel(50 mg/m2 I.V. in a one-hour infusion) and induction carboplatin (AUC 2.0 I.V. in a thirty-minute infusion): 1x/week for 6 weeks. Concurrent radiation therapy (RT): 1.8 Gy/day, 5 fx/week, for a total of 50.4 Gy in 28 fractions plus a boost of 1.8 Gy/day, 5 fx/week, for a total of 10.8 Gy in 6 fractions. Followed by an assessment to determine whether patient will undergo a resection or not. Followed by consolidation paclitaxel (200 mg/m2 I.V. over three hours) and consolidation carboplatin (AUC 6.0 over one hour) q 21 days x 2.
Radiação: Radioterapia
Medicamento: Induction Carboplatin
Medicamento: Induction Paclitaxel
Procedimento: Ressecção
Medicamento: Consolidation Carboplatin
Medicamento: Consolidation Paclitaxel

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Mediastinal Nodal Clearance Rate
Prazo: At completion of concurrent chemotherapy and radiation therapy, up to 14 weeks.
If at least 12 of the first 21 evaluable patients and at least 27 of the the first 45 evaluable patients have mediastinal nodal clearance (MNC), then a conclusion of a 70% MNC rate (compared to 50%) is made using Simon's two-stage design with 90% power and 10% type I error.
At completion of concurrent chemotherapy and radiation therapy, up to 14 weeks.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Percentage of Patients With Complete Pathological Response After Concurrent Chemotherapy and Radiation Therapy
Prazo: At time of surgery (16-18 weeks)
Complete pathologic response is defined as complete resection achieved and no evidence of viable tumor in the entire resection specimen.
At time of surgery (16-18 weeks)
Percentage of Patients With Major Surgical Morbidities Within 30 Days of Surgery
Prazo: From 0 to 30 days following surgery (surgery occurs within 16-18 weeks after registration)
The surgical morbidities occurring within 30 days following resection were assessed and graded using the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0. A major morbidity is considered a grade 3 or higher of any of the following: pneumonitis, infection, atelectasis, chest tube drainage/bronchial stump leak, pneumothorax, chylothorax, cardiac ischemia/infarction, pulmonary thrombosis/embolism, supraventricular atrial arrhythmia, ventricular arrhythmia, post-operative hemorrhage, pulmonary/upper respiratory fistula, pleural effusion, or death.
From 0 to 30 days following surgery (surgery occurs within 16-18 weeks after registration)
Percentage of Patients Able to Undergo Surgical Resection
Prazo: At time of surgery (16-18 weeks)
At time of surgery (16-18 weeks)
Distribution of R0, R1, and R2 Resections After Chemotherapy
Prazo: At time of surgery (16-18 weeks)
An R0 resection is defined as a complete resection of all disease with negative margins and the highest lymph node resected negative for residual tumor. An R1 resection is defined as a complete resection of all disease with pathology of positive margins, pathologic evidence of tumor cells in the highest lymph node resected in the mediastinum, or extracapsular nodal spread. An R2 resection is defined as gross residual disease left behind after surgical resection.
At time of surgery (16-18 weeks)
Overall Survival at Two Years
Prazo: From registration to two years
Overall survival time is defined as time from registration to the date of death from any cause. Overall survival rate is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact.
From registration to two years
Progression-free Survival at Two Years
Prazo: From registration to two years
Progression is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or the appearance of one or more new lesions. An event for progression-free survival is the first occurrence of progression or death due to any cause. Progression-free survival time is defined as the time from study entry to the the date progression or death, or last known follow-up (censored) if neither progression nor death occurred. Progression-free survival rate is estimated using the Kaplan-Meier method.
From registration to two years
Distribution of Highest Grade Adverse Event
Prazo: From start of treatment to end of follow-up, a maximum of 64.3 months
The number of patients whose highest grade adverse event (AE) reported was 3, 4, or 5 was calculated. Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE. Number of patients with highest grade of 3, 4, and 5 are presented.
From start of treatment to end of follow-up, a maximum of 64.3 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Radiation Therapy Oncology Group

Colaboradores

National Cancer Institute (NCI)

Investigadores

  • Investigador principal: Mohan Suntharalingam, MD, University of Maryland Greenebaum Cancer Center

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de setembro de 2004

Conclusão Primária (Real)

1 de abril de 2012

Conclusão do estudo (Real)

16 de maio de 2016

Datas de inscrição no estudo

Enviado pela primeira vez

9 de novembro de 2004

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de novembro de 2004

Primeira postagem (Estimativa)

9 de novembro de 2004

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de setembro de 2019

Última atualização enviada que atendeu aos critérios de controle de qualidade

4 de setembro de 2019

Última verificação

1 de setembro de 2019

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • RTOG-0229
  • CDR0000389508

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever